Companies /Healthcare
BridgeBio Pharma Inc
NASDAQ: BBIO Biotechnology
$76.80
▼ $0.56 (−0.72%) today
Markets closed · 5:30pm ET

BridgeBio Pharma (BBIO) Q3 2026 Earnings

Reported Oct 29, 2026, 4:03pm ET · SEC source
$-0.42
Beat +24.60%
EPS · est. $-0.56 GAAP

Includes recognition of a one-time $75.0 million BEYONTTRA sales milestone from Bayer in license and services revenue; net loss attributable to common stockholders also reflects $26.3 million (26,293 thousand) of preferred stock dividends and accretion.

$353.2M
Beat +19.41%
Revenue · est. $295.8M
1 quarter
Consecutive EPS beats

How Did BBIO Stock React to Q3 2026 Earnings?

% change · around the report
0+3%+6%Oct 29Oct 30report 4:03pm ETearnings−1.3%+4.7%
0+3%+6%Oct 29Oct 30earnings−1.3%+4.7%
BBIO +4.7%S&P 500 −1.3%
−3%0+3%+6%Oct 29Oct 30report 4:03pm ETearnings−2.3%+4.7%
−3%0+3%+6%Oct 29Oct 30earnings−2.3%+4.7%
BBIO +4.7%NASDAQ −2.3%
−5%0+5%+10%Oct 28Nov 6report 4:03pm ETearnings−3.8%+4.9%
−5%0+5%+10%Oct 28Nov 6earnings−3.8%+4.9%
BBIO +4.9%S&P 500 −3.8%
−6%0+6%Oct 28Nov 6report 4:03pm ETearnings−7.1%+4.9%
−6%0+6%Oct 28Nov 6earnings−7.1%+4.9%
BBIO +4.9%NASDAQ −7.1%
+5.97%
Day of report
+0.06%
Next session
−0.88%
One week

Did BBIO Beat Earnings? Q3 2026 Results

Yes. BridgeBio Pharma reported Q3 2026 earnings of $-0.42 a share on Oct 29, 2026, beating the $-0.56 consensus estimate by 24.6%. Revenue was $353.2M against a $295.8M estimate.

BridgeBio Pharma delivered a strong third quarter of 2026, beating Wall Street expectations on both the top and bottom lines as its ATTR-CM therapy Attruby continued to gain commercial traction. Revenue of $353.17 million topped the $295.75 million consensus by 19.41% and grew 192.6% year over year, driven primarily by U.S. Attruby net product revenue of roughly $253.20 million and a $75.00 million one-time BEYONTTRA sales milestone payment from Bayer that lifted license and services revenue to $79.30 million. On a GAAP basis, which reflects that Bayer milestone as well as $26.30 million in preferred stock dividends and accretion, the company reported a loss per share of $0.42, beating the consensus estimate of $0.56 by 24.60%. The operating loss narrowed sharply to $11.60 million from $145.20 million a year ago even as commercialization spending rose. With $1.50 billion in cash, management says the company is fully funded through three anticipated product launches, including PDUFA dates for BBP-418, oral infigratinib, and encaleret falling within a seven-month window beginning November 2026.

Key Takeaways
  • Attruby U.S. net product revenue up ~$145 million year over year and ~$31 million sequentially
  • Growth led by the treatment-naïve segment, with rising first-line share
  • $75.0 million BEYONTTRA sales milestone from Bayer recognized in license and services revenue
  • $16.2 million increase in royalty revenue from BEYONTTRA sales in the EU and Japan
  • SG&A up $63.2 million and R&D up $30.6 million on commercialization and late-stage development

“I'm heartened by how consistently the evidence for acoramidis keeps pointing in the same direction. This quarter we added two more large real-world comparisons to a growing body of data showing acoramidis outperforming tafamidis on the outcomes that matter most to patients: survival and hospitalizations.”

BridgeBio Pharma CEO, on the earnings call

What Is BridgeBio Pharma's Outlook?

BridgeBio expects cash, cash equivalents and marketable securities of $1.5 billion to fully fund three potential launches and expansion indications. Upcoming milestones include: - **BBP-418 (LGMD2I/R9):** PDUFA date November 27, 2026, with U.S. launch upon approval; EU MAA submission planned for the first half of 2028, based on FORTIFY Month 36 data expected late 2027/early 2028; pediatric (<12) studies to begin in the first half of 2027. - **Oral infigratinib (achondroplasia):** PDUFA date February 4, 2027; potential EU approval in the second half of 2027. - **Encaleret (ADH1):** PDUFA date May 8, 2027; potential EU approval in the second half of 2027. - **RECLAIM-HP (encaleret, chronic hypoparathyroidism):** topline data in early 2028. - **BBP-717:** IND submission in 2027. - **Acoramidis:** new data to be shared at AHA 2026.

BBIO YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$200.0M$120.7M$353.2MRevenue$-6,062,611$-11,639,000Operating Income$-33,562,171$-56,710,000Net Income
$0$200.0MRevenueOperating IncomeNet Income
BBIO income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $353.2M $120.7M +192.6%
Operating Income −$11.6M −$6.1M +92.0%
Net Income −$56.7M −$33.6M +69.0%

BBIO Revenue by Segment

Attruby$253.3M+134.3%
License and Services Revenue$79.3M+854.3%
Attruby (acoramidis) - U.S. Net Product Revenue
Attruby (acoramidis) - Net Product Revenue
Royalty Revenue$20.5M+379.5%
BEYONTTRA Royalty Revenue

Figures from SEC filings and company reports. Not investment advice.